News & Updates

The third-generation human epidermal growth factor receptor 2 (HER2)-directed antibody‒drug conjugate (ADC) SHR-A1811 has passed its phase II trial, demonstrating safety and efficacy in the neoadjuvant setting for patients with HER2-positive breast cancer.

Half of breast cancer survivors in Hong Kong who recently received the diagnosis experienced a moderate-to-severe level of psychological distress during the COVID-19 pandemic, a cross-sectional study has shown.

In a study presented at EASL 2025, the use of statins appears to be associated with a reduced risk of hepatocellular carcinoma (HCC) and slower progression of liver fibrosis in individuals with chronic liver disease (CLD).

Treatment-naive patients with immediate-risk (IR) nonmuscle-invasive bladder cancer (NMIBC) who received gemcitabine appear to have greater recurrence risk than those given Bacillus Calmette-Guerin (BCG). Both treatments, however, are effective against disease progression.

A network meta-analysis (NMA) reports that the combination regimen comprising atezolizumab and bevacizumab appears to be better than other first-line systemic therapeutic alternatives for advanced hepatocellular carcinoma (HCC) in terms of providing a balance between overall survival (OS) benefit and quality of life (QoL) preservation.